M<sub>1</sub>/M<sub>4</sub>-Preferring Muscarinic Cholinergic Receptor Agonist Xanomeline Reverses Wake and Arousal Deficits in Nonpathologically Aged Mice-Reference-Cited by-同舟云学术

M₁/M₄-Preferring Muscarinic Cholinergic Receptor Agonist Xanomeline Reverses Wake and Arousal Deficits in Nonpathologically Aged Mice

Published:2023-01-19 Issue:3 Volume:14 Page:435-457
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Russell Jason K.¹^ORCID,Ingram Shalonda M.¹,Teal Laura B.¹^ORCID,Lindsley Craig W.¹^ORCID,Jones Carrie K.¹

Affiliation:

1. Department of Pharmacology, Warren Center for Neuroscience Drug Discovery, and Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States

Funder

National Institute on Aging

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.2c00592

Reference57 articles.

1. The Cholinergic Hypothesis of Geriatric Memory Dysfunction

2. The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development

3. Contribution of the Cholinergic System to Verbal Memory Performance in Mild Cognitive Impairment

4. Acetylcholine esterase activity in mild cognitive impairment and Alzheimer’s disease

5. The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for Achieving Better Cognitive Health in Individuals with Schizophrenia Spectrum: A Focus on the Canadian Landscape: Stratégies pour atteindre une meilleure santé cognitive chez les personnes souffrant du spectre de la schizophrénie : un regard sur le paysage canadien;The Canadian Journal of Psychiatry;2024-07-25

2. Muscarinic Receptors and Alzheimer’s Disease: New Perspectives and Mechanisms;Current Issues in Molecular Biology;2024-07-02

3. Muscarinic Receptor Activators as Novel Treatments for Schizophrenia;Biological Psychiatry;2024-03

4. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal;Expert Opinion on Investigational Drugs;2023-11-29

5. Vesicular acetylcholine transporter in the basal forebrain improves cognitive impairment in chronic cerebral hypoperfusion rats by modulating theta oscillations in the hippocampus;Neuroscience Letters;2023-06